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Neurofibromatosis  type  1  (von  Recklinghausen's  disease,  NF-1)  is  an  autosomal-dominant  neurocutaneous  disorder 
characterized  by  abnormal  skin  pigmentation  (café  au  lait  spots  and  axillary  freckling),  cutaneous  and  plexiform 
neurofibromas,  skeletal  dysplasias,  and  Lisch  nodules  (pigmented  iris  hamartomas).  Gastrointestinal  stromal  tumors 
(GISTs)  are  the  most  common  tumors  of  mesenchymal  origin  in  the  gastrointestinal  tract,  mesentery,  omentum,  and 
retroperitoneum.  Here,  we  report  a  case  of  GIST  in  the  ileum  of  a  76-year-old  woman  previously  diagnosed  as  NF-1. 
She  was  admitted  due  to  sudden  onset  of  abdominal  pain.  Contrast  enhanced  CT  scan  revealed  a  moderately  defined, 
peripherally  enhanced  soft  tissue  mass  of  about  8.8×7.3cm,  originating  from  the  small  bowel  in  the  left  of  the 
abdomen.  Surgical  excision  was  performed  and  the  tumor  was  found  to  be  composed  of  tumor  cells  that  were  positive 
for  c-kit  protein.  The  patient  started  imatinib  treatment  a  month  later,  but  stopped  medication  due  to  dyspepsia  after 
a  few  months  and  eventually  progressed  after  18  months 
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INTRODUCTION
Neurofibromatosis  type  1  (von  Recklinghausen's  disease, 
NF-1)  is  a  relatively  common  autosomal-dominant  neurocutaneous 
disorder  characterized  by  abnormal  skin  pigmentation  (café  au 
lait  spots  and  axillary  freckling),  cutaneous  and  plexiform 
neurofibromas,  skeletal  dysplasias,  and  Lisch  nodules 
(pigmented  iris  hamartomas).  The  genetic  abnormality  in 
neurofibromatosis  has  been  localized  to  the  neurofibromatosis  1 
gene  on  chromosome  17,  which  is  a  tumor  suppressor  gene  in 
some  cell  types
1).  Abnormal  tumor  suppression  increases  the 
incidence  of  benign  and  malignant  neoplasia  in  children  and 
adults  with  NF-1.  Optic  pathway  gliomas  and  neurofibromas  are 
the  most  common  neoplasms  occurring  in  patients  with 
neurofibromatosis
1).
Gastrointestinal  abnormalities  in  patients  with  NF-1  are 
reported  to  occur  in  up  to  10～25%  of  patients  and  consist  of 
four  groups  of  lesions:  mesenchymal  neoplasms;  hyperplasias 
of  intestinal  neural  tissue;  neuroendocrine  tumors  of  the 
duodenum;  and  rarely,  other  gastrointestinal  neoplasms  such  as 
adenocarcinomas
2).  Although  neurofibromas  are  the  most 
commonly  encountered  mesenchymal  neoplasm  of  the  gastro-
intestinal  tract  in  patients  with  NF-1,  Gastrointestinal  stromal 
tumors  (GISTs),  leiomyomas,  and  leiomyosarcomas  also  occur
3).
GISTs  are  the  most  common  tumors  of  mesenchymal  origin 
in  the  gastrointestinal  tract,  mesentery,  omentum,  and 
retroperitoneum.  The  most  significant  risk  factor  for  development 
of  these  tumors  is  the  presence  of  NF-1
5).  Other  risk  factors 
include  urticaria  pigmentosa  and  the  very  rare  familial  GIST 
syndrome.
Although  the  increased  incidence  of  GIST  in  patients  with 
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Figure  1.  Small-bowel  GIST  with  a  diffusely  thickened  bowel  wall. 
Central  portion  of  the  tumor  has  an  area  of  necrosis,  with  air 
present  within  the  necrotic  cavity  that  communicates  with  the 
lumen  of  the  small  bowel.
Figure  2.  Histologically,  the  tumors  were  composed  of  multiple 
spindle  cells  with  eosinophilic  cytoplasm  and  ovoid  to  elongated 
nuclei.  The  number  of  mitosis  was  13/50HPF  (hematoxyline-eosin, 
×200).
Figure  3.  Immunohistochemistry  showing  positive  for  the  surface 
tyrosine kinase receptor c-Kit (CD-117), the defining characteristics 
of  GIST  (×200).
English,  this  association  has  rarely  been  documented  in  Korea. 
Here  we  report  a  case  of  GIST  in  the  ileum  of  a  76-year-old 
woman  diagnosed  as  NF-1.
CASE REPORT
A  previously  healthy  76-year-old  woman  who  was  diagnosed 
with  NF-1  40  years  ago  presented  with  sudden  onset  of  left 
lower  quadrant  pain.  When  she  visited  the  emergency  room, 
vital  signs  were  blood  pressure  100/60  mmHg,  pulse  rate 
96/minute,  respiratory  rate  20/min,  and  body  temperature  37℃. 
The  physical  examination  revealed  a  palpable  nonpulsatile  mass 
in  the  left  flank  area,  which  showed  tenderness  and  rebound 
tenderness.  There  were  numerous  café-au-lait  patches  and 
multiple  cutaneous  neurofibromas  on  the  upper  extremities  and 
trunk.
When  admitted,  CBC  showed  leukocytes  4,880/mm
3 
(segmented  neutrophils  85.9%),  hemoglobin  5.6  g/dL,  and 
platelets  218,000/mm
3.  Blood  chemistry  results  were  protein  5.7 
g/dL,  albumin  3.1  g/dL,  total  bilirubin  0.5  mg/dL,  alkaline  phosphatase 
144  IU/L,  AST/ALT  26/14  IU/L,  and  BUN/creatinine  26/1.2  mg/dL. 
There  were  no  significant  findings  for  electrolytes  or  urinalysis.
A  contrast  enhanced  CT  scan  was  performed  and  it  revealed 
a  soft  tissue  mass  in  the  small  bowel  suggesting  a  diagnosis  of 
GIST  (Figure  1).
On  the  basis  of  the  radiological  finding,  the  ileal  tumor  was 
surgically  excised.  A  gelatine-like,  ruptured  mass  in  very  fragile 
state  originating  from  the  bowel  wall  was  located  just  below  the 
Treiz  ligament.  There  were  multiple  fibrotic  nodules  though  the 
whole  small  bowel.  The  fragmented  mass  measured  13.0×3.0
×4.0  cm  in  total  and  was  a  brown  tan  color  with  a  hemorrhagic 
appearance.  The  cut  section  showed  a  fishy-flesh  appearance. 
A  second  mass  measuring  4.0×3.0×2.0  cm  had  an  irregular 
shape  and  was  attached  to  the  omentum.  Its  cut  section  was 
also  a  brown  tan  color  with  a  fish-fleshy  appearance.  The 
tumors  were  composed  of  tumor  cells  that  were  positive  for 
c-kit  protein  and  the  number  of  mitosis  was  13/50  high  power 
fields  (HPF)  (Figure  2  and  3).
As  the  tumor  was  found  by  biopsy  to  be  a  GIST,  the  patient 
started  receiving  imatinib  a  month  later.  After  a  few  months 
however,  she  stopped  medication  due  to  dyspepsia  and 
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DISCUSSION
Neurofibromatosis  type-1  (von  Recklinghausen  disease)  is  an 
autosomal  dominant  hereditary  disease  that  may  affect  the 
gastrointestinal  tract  in  up  to  25%  of  patients
2, 6, 7).  Stromal 
tumors  have  been  reported  to  be  the  most  common  lesion  of 
the  gastrointestinal  tract,  but  the  symptomatic  cases  account  for 
less  than  5%  of  patients
2, 8).  These  tumors  may  cause 
obstruction,  volvulus,  intussusception,  ulcertation,  bleeding  or 
perforation.  In  our  patient,  bleeding  of  ruptured  tumors  caused 
hemoperitoneum.
GISTs  in  patients  with  NF-1  usually  occur  in  their  middle-age 
after  the  appearance  of  cutaneous  manifestations
2).  GISTs  in 
patients  with  NF-1  are  histologically  and  immunophenotypically 
identical  to  those  in  patients  without  NF-1.  Although  most 
GISTs  arise  in  the  stomach,  a  search  in  the  pathology  literature 
shows  that  GISTs  in  patients  with  NF-1  tend  to  be  multiple  and 
to  be  located  predominantly  within  the  small  intestine
4).
Clinical  symptoms  are  related  to  the  size  and  location  of  the 
GISTs.  Most  pathologists  use  a  combination  of  tumor  size  and 
mitotic  rate  to  assess  the  malignant  potential  of  these  tumors.  In 
general,  malignant  GISTs  are  larger,  more  cellular,  and  more 
mitotically  active.  GISTs  that  are  smaller  than  5  cm  with  five 
mitoses  per  50  consecutive  high-power  fields  or  less  are 
considered  to  be  benign  with  a  low  risk  for  metastasis.  Tumors 
larger  than  10  cm  with  more  than  five  mitoses  per  50 
high-power  fields  are  considered  to  be  malignant.  All  tumors 
falling  between  these  two  extremes  are  considered  to  be  of 
uncertain  malignant  potential  with  intermediate  risk  for 
metastasis.  Tumors  with  more  than  50  mitoses  per  50 
high-power  fields  are  considered  to  be  highly  malignant  with  an 
aggressive  clinical  behavior.  The  liver  and  the  peritoneum  are 
the  most  common  sites  of  spread  in  malignant  GISTs
5). 
This  case  illustrates  the  increased  prevalence  and  associa-
tion  of  GISTs  in  patients  with  NF-1.  A  medical  history  of  NF-1 
in  a  patient  who  has  an  intra-abdominal  mass  with  nonspecific 
CT  features  and  central  liquefaction  may  help  in  diagnosing 
GIST  by  virtue  of  the  well-known  association  of  these  two 
entities.
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